TABLE 2

Prevalence of COVID-19-related symptoms at 3-, 6- and 12-month follow-up in patients after hospitalisation for COVID-19

3 months (n=385) n (%)6 months (n=483) n (%)12 months (n=271) n (%)p-value#
Physical symptoms
Muscle weakness220 (57.1)234 (48.4)111 (41.0)<0.001
Balance problems/dizziness169 (43.8)213 (44.4)116 (42.8)0.922
Joint pain166 (43.2)201 (41.6)111 (41.0)0.352
Tingling/numbness in extremities147 (36.8)163 (33.9)86 (32.1)0.291
Hair loss138 (35.9)98 (20.3)35 (12.9)<0.001
Headache#33 (31.4)57 (26.1)29 (18.6)0.579
Chest pain#29 (29.0)40 (18.4)28 (17.8)0.069
Skin rash99 (25.7)132 (27.4)82 (30.3)0.587
Vision problems97 (25.2)148 (30.6)78 (28.8)0.023
Hoarseness91 (23.6)125 (25.9)57 (21.0)0.088
Anosmia84 (21.9)93 (19.3)53 (19.6)0.369
Ageusia82 (21.2)94 (19.5)52 (19.2)0.185
Stool problems68 (17.7)89 (18.5)41 (15.1)0.547
Claudication54 (14.1)68 (14.1)27 (10.0)0.116
Hearing problems52 (13.5)70 (14.5)53 (19.6)0.059
Miction problems37 (9.7)58 (12.1)34 (12.5)0.269
Respiratory symptoms
Exertional dyspnoea315 (81.8)345 (71.4)171 (63.1)<0.001
Dyspnoea#78 (66.1)114 (51.8)83 (52.9)0.003
Cough112 (29.0)119 (24.7)66 (24.4)0.329
Phlegm98 (25.5)117 (24.2)67 (24.7)0.727
Fatigue symptoms
Fatigue243 (64.5)277 (63.1)156 (60.2)0.932
Sleeping problems141 (36.5)172 (35.6)96 (35.4)0.777
Cognitive symptoms
Memory problems211 (54.7)271 (56.1)158 (58.3)0.144
Concentration problems206 (53.4)249 (51.6)140 (51.7)0.826
Sensory overload#44 (45.5)93 (43.9)58 (36.7)0.503
Anxiety/nightmares56 (14.5)72 (14.9)40 (14.8)0.785

Data are presented as n (%) indicating the number of patients with symptoms. p-values are obtained from Generalised Estimating Equation analyses, with follow-up visit as fixed factor and symptom (yes/no) at each follow-up visit as dependent variable. Bonferroni correction was applied for multiple testing; a p-value <0.002 was considered statistically significant (printed in bold). #: symptoms headache, chest pain, dyspnoea and sensory overload were added at a later stage, resulting in lower total numbers.